GEN Exclusives

More »

GEN News Highlights

More »
Apr 24, 2007

MultiCell Enters Licensing Contract with Eisai

  • MultiCell Technologies granted Eisia a five-year nonexclusive license to aid in its drug discovery program. Eisai will use MultiCell's Fa2N-4 immortalized human hepatocyte cells and MFE™ culture media for discovery and ADME-Tox applications at its Tsukuba Research Laboratories in Japan.

    "Eisai has been using our Fa2N-4 cells and culture media for several years under a sublicense agreement granted by XenoTech LLC, our previous licensee,” points out ," points out Stephen Chang, president and CEO of Multicell.

    “Our new, direct agreement with Eisai is another validation of the value of our proprietary immortalized cell lines for drug discovery/ADME-Tox applications.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?